|

SX-682 Clinical Trials

4 actively recruiting trials across 3 locations

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 2

Top Sponsors

  • University of Rochester1
  • Syntrix Biosystems, Inc.1
  • National Cancer Institute (NCI)1
  • Institute of Cancer Research, United Kingdom1

Indications

  • Cancer4
  • Metastatic Castrate Resistant Prostate Cancer (mCRPC)1
  • Metastatic Castration-resistant Prostate Cancer1
  • Pancreatic Ductal Adenocarcinoma1
  • Pancreatic Cancer1

Other1 trial

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Phase 1/2

Los Angeles, California1 trial

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

University of California, Los Angeles

Phase 2

Bethesda, Maryland1 trial

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

National Institutes of Health Clinical Center

Phase 1/2

Rochester, New York1 trial

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

University of Rochester

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.